Wiley, Henry E <br/><br/>
A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.  [electronic resource] 

 -  Ophthalmology  Apr 2016 
 - 841-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-4713 
<br/><br/><label>Standard No.: </label>10.1016/j.ophtha.2015.11.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Bevacizumab--administration & dosage<br/>Cross-Over Studies<br/>Diabetes Mellitus, Type 1--complications<br/>Diabetes Mellitus, Type 2--complications<br/>Diabetic Retinopathy--drug therapy<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Macular Edema--drug therapy<br/>Male<br/>Middle Aged<br/>Ranibizumab--administration & dosage<br/>Research Design<br/>Retina--pathology<br/>Tomography, Optical Coherence<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--drug effects